Neurogenic Detrusor Overactivity Market Report 2026

The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.82 billion in 2025 to $1.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to limited treatment options for NDO, reliance on conventional surgical interventions, growing prevalence of neurogenic bladder disorders, increasing hospital and urology clinic infrastructure, lack of patient and caregiver education.

The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to development of novel pharmacological therapies, advancement in minimally invasive surgical procedures, integration of neuromodulation devices, increasing adoption of continuous patient monitoring technologies, rising investment in long-term care and rehabilitation services. Major trends in the forecast period include rising adoption of antimuscarinic and beta-3 adrenergic agonists, increased use of neuromodulation and minimally invasive therapies, expansion of behavioral therapy and patient training programs, growing focus on urodynamic and ultrasound monitoring, increasing awareness of quality of life assessment and long-term care.

The increasing incidence of neurological disorders is anticipated to drive the growth of the neurogenic detrusor overactivity market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, or peripheral nerves, resulting in impairments related to movement, sensation, cognition, or other bodily functions. The prevalence of neurological disorders is rising as life expectancy increases, leading to a higher likelihood of age-related neurological degeneration. Neurogenic detrusor overactivity (NDO) is a bladder dysfunction frequently linked to neurological conditions such as spinal cord injury, multiple sclerosis, and Parkinson’s disease. These disorders interfere with normal nerve communication between the brain and the bladder, causing involuntary bladder contractions. For instance, in April 2024, according to a study published by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, global cases of brain disorders are projected to reach approximately 4.9 billion by 2050. Therefore, the rising incidence of neurological disorders is fueling the growth of the neurogenic detrusor overactivity market.

Major companies operating in the neurogenic detrusor overactivity (NDO) treatment market are concentrating on the development of advanced generic therapies, such as beta-3 adrenergic receptor agonists, to provide effective bladder control solutions at lower costs. Beta-3 adrenergic receptor agonists, including mirabegron, work by relaxing the detrusor muscle of the bladder, thereby increasing bladder capacity and reducing symptoms such as urgency and urinary incontinence. For example, in April 2024, Lupin Ltd., an India-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, the generic version of Myrbetriq, in the United States. As a once-daily oral therapy, Mirabegron offers a convenient and effective treatment option for patients with overactive bladder (OAB) and neurogenic detrusor overactivity (NDO), including pediatric populations. This approval highlights Lupin’s focus on expanding access to high-quality, affordable generic medicines across key therapeutic areas.

In November 2024, Boston Scientific Corporation, a US-based medical device company, acquired Axonics, Inc. for an undisclosed amount. Through this acquisition, Boston Scientific seeks to expand its neuromodulation and urology portfolio by integrating Axonics’ advanced sacral neuromodulation technologies, strengthen its position in treating patients with overactive bladder and other urinary and bowel dysfunctions, and enhance its ability to deliver comprehensive solutions for pelvic health conditions. Axonics, Inc. is a US-based medical technology company specializing in sacral neuromodulation (SNM) systems designed to improve control of overactive bladder symptoms.

Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.

North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurogenic detrusor overactivity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the neurogenic detrusor overactivity market by increasing costs for imported medications, neuromodulation devices, and surgical equipment. Segments such as botulinum toxin injections, augmentation cystoplasty tools, and urodynamic monitoring devices are particularly impacted, with regions like North America and Asia-Pacific facing higher import duties. This has resulted in increased treatment costs and supply chain adjustments. On the positive side, tariffs are encouraging local manufacturing, domestic device innovation, and diversification of sourcing strategies, which could strengthen regional capabilities.

The neurogenic detrusor overactivity market research report is one of a series of new reports that provides neurogenic detrusor overactivity market statistics, including neurogenic detrusor overactivity industry global market size, regional shares, competitors with a neurogenic detrusor overactivity market share, detailed neurogenic detrusor overactivity market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenic detrusor overactivity industry. This neurogenic detrusor overactivity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurogenic detrusor overactivity (NDO) is a bladder disorder resulting from neurological conditions that interfere with normal nerve communication between the brain, spinal cord, and the bladder’s detrusor muscle. This disturbance causes excessive or involuntary detrusor muscle contractions, leading to symptoms such as urinary urgency, increased frequency, urge incontinence, and, in some cases, incomplete bladder emptying.

The primary treatment types for neurogenic detrusor overactivity (NDO) include non-surgical treatment, surgical treatment, and follow-up treatment. Non-surgical treatment involves medical management or therapeutic approaches that control or alleviate the condition without requiring invasive surgical intervention. These treatments are applied across different patient groups, including adults and children, and are utilized by various end users such as hospitals, urology clinics, rehabilitation centers, private practices, and long-term care facilities.

The neurogenic detrusor overactivity market includes revenues earned by entities by providing services such as medication management, behavioral and lifestyle interventions, physiotherapy, absorbent products and skin care, and catheterization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.